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Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide 
and the third leading cause of cancer deaths. microRNAs (miRNAs) are evolutionary 
conserved small non-coding RNA that negatively regulate gene expression and protein 
translation. Recent evidences have shown that they are involved in many biological 
processes, from development and cell-cycle regulation to apoptosis. miRNAs can behave 
as tumor suppressor or promoter of oncogenesis depending on the cellular function of their 
targets. Moreover, they are frequently dysregulated in HCC. In this review we summarize 
the latest findings of miRNAs regulation in HCC and their role as potentially diagnostic 
and prognostic biomarkers for HCC. We highlight development of miRNAs as potential 
therapeutic targets for HCC. 
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1. Introduction 
Hepatocellular carcinoma (HCC) is the most common cancer of the liver, the fifth most frequently 
diagnosed cancer and the third leading cause of cancer-related deaths in the World, with an annual 
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mortality of about 700,000 persons [1]. An estimated 80%–90% of HCCs develop in cirrhotic liver as 
a consequence of chronic viral hepatitis B (HBV) or C (HCV) [2]. HCC has a very low overall 5-year 
survival rate, ranging from 0% to 14% from the time of clinical diagnosis because it is difficult to 
diagnose HCC in its early stages [3,4]. Moreover, resistance to treatment, tumor recurrence or 
progression, and metastasis call for novel sensitive and specific molecular biomarkers for early 
diagnosis, to predict prognosis and to develop more effective therapeutic strategies able to improve the 
clinical outcome of HCC. 
MicroRNAs (miRNAs) are a class of short (20–25 nucleotides in lenght) non-coding RNAs. To 
date, there are 1,870 human miRNA sequences registered in the miRBase database [5]. miRNA control 
the stability and translation of targeted messenger RNAs (mRNAs) through complementary interaction 
with the 3' untranslated region of target genes (or of complementary sequences). They are estimated to 
regulate expression of about one-third of human genes [6,7]; one miRNA can interact with hundreds of 
genes. Therefore, it will not be surprising that even a single type of miRNA may enable normal cells to 
be transformed into cancerous cells [8–12]. miRNAs indeed are involved in fundamental cellular 
processes, like embryonic development, differentiation, cell cycle, metabolism, and in carcinogenesis 
and tumor progression [13–17]. Here, we review miRNAs biogenesis, their alterations and their role in 
the diagnosis and treatment of HCC. 
2. miRNAs Biogenesis 
miRNAs are transcribed by the polymerase II as primary miRNA (pri-miRNAs); these transcripts 
are processed in the nucleus by ribonuclease III Drosha in combination with its cofactor,  
DGCR8 (DiGeorge syndrome critical region gene 8) into a precursor miRNA (pre-miRNA). This  
70-90-nucleotide hairpin-shaped pre-miRNA is exported to the cytoplasm by exportin-5 and is further 
cleaved by another nuclease, Dicer, and its partner, HIV-1 transactivating response RNA binding protein 
(TRBP), to form an 18–25 nucleotides miRNA duplex [18,19]. While the passenger miRNA strand is 
typically degradated, the guide strand is incorporated into the RNA-induced silencing complex (RISC) 
and then mediate mRNA degradation or translational inhibition, based on the level of complementary 
base pairing between the miRNA and the 3' untranslated region (UTR) of target mRNA [20]. 
3. miRNAs and HCC 
miRNAs are characterized by key regulatory functions and regulate many biological processes; 
alterations in their expression contribute to cancer. In fact, the involvement of miRNAs in 
tumorigenesis and tumor progression is well established, as they can behave as tumor suppressor or 
promoter of oncogenesis depending on the cellular function of their targets [21]. 
In particular, various miRNAs were deregulated (or are aberrantly expressed) in human HCC  
(Table 1) [22]. In most cases, HCC originates on a background of cirrhosis, a chronic and diffuse 
hepatic disease that results from continuous liver injury and regeneration, due to different etiological 
factors. Different etiologies of HCC play a role in the different miRNA expression profiles. 
Molecules 2014, 19 6395 
 
Table 1. miRNAs deregulated in hepatocellular carcinoma (HCC). 
miRNAs Molecularalteration Targets Characteristics 
miR-10a Upregulated EphA4, CADM1 EMT, metastasis 
miR-17-5p Upregulated p38 pathway 
Multiple tumor nodules, vein 
invasion, shortened overall 
survival 
miR-18a Upregulated ER1a 
Poor prognosis, poor 
differentiation, proliferation 
miR-18b Upregulated TIMP3 
Cell growth; tumorigenesis; 
metastasis 
miR-21 Upregulated C/EBPb, RhoB, PDCD4, PTEN Drugresistance, metastasis 
miR-23a Upregulated PGC-1a,G6PC  Gluconeogenesis 
miR-130a Upregulated RUNX3 Drugresistance 
miR-135a Upregulated FOXM1, MTSS1 Metastasis 
miR-143 Upregulated FNDC3B Metastasis 
miR-155 Upregulated SOCS1, DKK1, APC, PTEN 
High recurrence and poor 
prognosis following OLT, 
proliferation, tumorigenesis 
miR-210 Upregulated VMP1, AIFM3  
Metastasis; apoptosis; 
proliferation 
miR-216a Upregulated TSLC1 Tumorigenesis 
miR-221 Upregulated 
CDK inhibitors, p27, p57, Arnt, 
Bmf 
Multinodularity, reduced time to 
recurrence, gain of metastatic 
properties, angiogenesis, 
apoptosis, proliferation, high 
tumor capsular infiltration 
miR-224 Upregulated 
NF-kB pathways, Atg5, Smad4, 
autophagy, API-5 
Proliferation, apoptosis, 
metastasis 
miR-301a Upregulated Gax Metastasis 
miR-373 Upregulated PPP6C Cell cycle 
miR-490-3p Upregulated ERCIC3 EMT 
miR-519d Upregulated 
CDKN1A/p21; PTEN; AKT3; 
TIMP2 
Proliferation, invasion, apoptosis 
miR-550a Upregulated CPEB4 Metastasis 
miR-590-5p Upregulated TGF-beta RII Metastasis, proliferation 
miR-615-5p Upregulated IGF-II Cell growth, migration 
miR-657 Upregulated TLE1, NF-jB Proliferation 
let-7 
a,b,c,d,f,g  
Downregulated STAT3 
Apoptosis, proliferation, 
earlyrecurrence 
miR-1 Downregulated ET1 Proliferation 
miR-7a Downregulated 
PIK3CD, Caspase-3, HMGA2, 
C-myc, Bcl-xl 
Proliferation, apoptosis, 
tumorigenesis, metastasis 
miR-26a/b Downregulated IL-6, CyclinD2, E2 Poorsurvival 
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Table 1. Cont. 
miRNAs Molecularalteration Targets Characteristics 
miR-34a Downregulated CCL22, c-met Metastasis 
miR-101 Downregulated 
EZH2, EED, SOX-9, DNMT3A, 
Mcl1, Fos 
Advanced tumor progression, 
poor prognosis, apoptosis; DNA 
methylation 
miR-122 Downregulated 
c-Myc, Bcl-w, ADAM-1, Wnt-1, 
MTTP, IL-6, TNF, IGF-1R, 
Cyclin G1 
Gain of metastatic properties, 
early recurrence, angiogenesis, 
apoptosis 
miR-124 Downregulated 
ROCK2, EZH2, PIK3CA, CDK6, 
VIM, SMYD3, IQGAP1 
Proliferation 
miR-
125a/125b  
Downregulated 
MMP11, SIRT7, VEGF-A, 
LIN28B2, Bcl-2, Mcl-1, Bcl-w 
Angiogenesis, apoptosis, 
metastasis, proliferation[ 
miR-138 Downregulated CCND3 Cell cycle 
miR-139 Downregulated ROCK2, c-fos Metastasis 
miR-145 Downregulated 
IRS1, IRS2, IGF-1R, b-catenin, 
OCT4 
Insulin-like growth factor 
pathway, stem-like cells 
tumorigenicity 
miR-195 Downregulated 
NF-jB pathway, VEGF, VAV2, 
CDC42, Cyclin D1, CDK6, E2F3 
Proliferation, apoptosis, 
tumorigenicity 
miR-
199a/b-3p  
Downregulated 
PAK4, c-Met, mTOR, DDR1, 
caveolin-2 
Reduced time to recurrence, poor 
overall survival and progression-
free survival rates, proliferation, 
autophagy, metastasis 
miR-200a Downregulated HDAC4 Proliferation, metastasis; 
miR-203 Downregulated ABCE1 Proliferation 
miR-214 Downregulated HDGF, catenin 
Proliferation, angiogenesis, 
metastasis 
miR-219-5p Downregulated GPC3 Proliferation 
miR-223 Downregulated STMN1 
Predictor of overall survival and 
recurrence-free survival after LT 
miR-375 Downregulated ATG7, AEG-1 Autophagy 
miR-376a Downregulated PIK3R1 Apoptosis, proliferation 
miR-449 Downregulated c-MET Apoptosis, proliferation 
miR-450a Downregulated DNMT3a Proliferation 
miR-520e Downregulated MEKK2; cyclin D1 Cell growth, proliferation 
Cellular miRNAs, like miR-155 and miRNA-18a, seem able to regulate HBV infection at the 
transcription level either by targeting cellular transcription factors required for HBV gene expression 
or by a directly binding to HBV transcripts [23–25]. miRNAs can target important players in DNA 
methylation and histone modification that play crucial roles in HBV cccDNA transcription [26,27]. On 
the other hand, HBV encoded proteins can influence cellular miRNA expression [28]. 
HCV chronic infection is another independent etiological factor for HCC. miR-196 plays a 
protective role in HCV-induced HCC by upregulating hemeoxygenase 1 (HMOX1) expression and 
inhibiting HCV transcription [29]. 
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Cirrhosis caused by chronic alcohol consumption is a risk factor of HCC especially in western 
countries. miR-217 could promote ethanol-induced fat accumulation in hepatocytes by downregulating 
SIRT1 [30] and miR-126 was found decreased in alcohol-related HCC [31]. In a preclinical model, 
mice with an ethanol-containing diet, miR-199 and miR-200, commonly downregulated in HCC, were 
found decreased. 
miRNAs are also involved in the pathogenesis of Non Alcoholic Steato Hepatitis (NASH), an 
increasingly important risk factor for HCC in recent years. 
Unsaturated fatty acids have been shown to increase miR-21 expression which downregulates the 
expression of tumor suppressor phosphatase and tensin homolog (PTEN) [32]. MiR-155, which targets 
another tumor suppressor C/EBP-ߚ is consistently upregulated in choline-deficient and amino  
acid-defined (CDAA) fed mice [24]. 
Many studies have shown differences of miRNAs expression in HCC tissues compared to  
non-tumoral tissues. An important note is that these works are qualitatively heterogenic, as each study 
identify a unique profile. This can be due to various factors, first the variability in the technical 
procedure: studies have been performed using the three most common detection methods such as 
microarray, RT-qPCR and next-generation sequencing (NGS). 
Hou et al. performed their study using NGS, which is a high-throughput technology that provides 
global information on all miRNAs in a sample [33]. They analyzed the miRNomes in human normal 
liver, hepatitis liver, and HCC. They found nine miRNAs accounted for ~88.2% of the miRNome in 
human liver. The three most represented miRNAs were mRr-122, miR-192, and miR 199 a/b-3p. In 
HCC miR-199a/b-3p is consistently decreased, this is associated with poor prognosis. Furthermore, 
both in vitro and in vivo, the PAK4/Raf/MEK/ERK pathway is inhibited by miR-199a/b-3p targeting 
tumour-promoting PAK4 to suppress HCC growth. In this study the expression of miR-122 decreased 
only in half of the HCCs and that is poorly relevant for survival. In contrast, there are many studies 
that described a tumourigenic role of miR-122 [8,34–36], including Gramantieri et al. who found that 
35 miRNAs, including miR-122, differ between HCC and cirrhosis. A recent study performed with 
microarray, which is based on annealing of DNA oligonucleotides to the homologous sequences, on a 
microchip, identified 40 miRNAs with significantly different expression between normal and HCC cell 
lines. Hierarchical clustering analysis showed up-regulated hsa-miR-1308 and down-regulated  
hsa-miR-122 as the top two differently expressed miRNAs [37]. 
These studies associated loss of miR-122 expression in HCC with poor prognosis and metastasis.  
In fact, the liver-specific miR-122 is the most abundant miRNA in the liver, modulates hepatic  
lipid metabolism and it plays an important role in regulating hepatocyte development and 
differentiation [38,39]. Loss of its expression correlates with impairment of mitochondrial  
metabolism [40]. On the contrary, restoration of miR-122 reduces the invasion, migration, and growth 
of metastatic liver cancer cells [41]. It functions as a potential tumour suppressor in two ways: 
inhibiting hepatic cell growth by targeting cyclin G1 and promoting apoptosis of hepatic cells by 
targeting BCL-w and ADAM17 involved in metastasis [33,41,42]. Besides miR-122, there are many 
miRNAs, with upregulation (miR-21, miR 221, miR224) or down regulation (miR-223, miR-1,  
miR-101), that are involved in promoting loss of cell cycle control in HCC [8,11,43–47]. miR-21 
promotes cell proliferation and tumor invasiveness in HCCs by targeting PTEN, PDCD4, and RECK [48].  
miR-221 promotes the cell-cycle progression by suppressing the expression of cyclin-dependent kinase 
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inhibitors CDKN1B/p27 [49] and CDKN1C/p57 [11]. Down regulation of miR-1 and miR-101 inhibits 
apoptosis of HCC cells and silencing miR-1 mediate HCC cell invasion [46,47]. Upregulation of  
miR-155 promote hepatocyte proliferation and tumor genesis by increasing Wnt signalling [23,50]. 
Instead, some miRNAs (miR-9, miR-143, miR-30d, and miR-151) have been shown to promote HCC 
metastasis [51,52]. 
Hence, miRNAs expression can be modified by mutations [53], polymorphisms (SNPs) [54,55], 
transcriptional deregulation, defects in the miRNAs biogenesis machinery [56], and epigenetic  
changes [57], such as DNA methylation that silences genes that encode miRNAs. Recently other 
miRNAs (miR-494, miR-429, miR-101) have shown their relevance in HCC [58–60]. 
4. miRNAs in HCC Diagnosis 
Since the reliability of laboratory analysis biomarkers [α-fetoprotein (AFP) and des-γ-carboxy-
prothrombin (DCP)] is still questionable, the accuracy of AFP is modest, especially in benign liver 
diseases, such hepatitis and cirrhosis and the elevated DCP activity is only ~50% of HCC patients with 
tumours <3 cm [61,62], novel biomarkers for early HCC diagnosis are urgently needed. miRNAs have 
been very promising as diagnostic markers of HCC. In fact, miRNAs are stable in human serum/plasma as 
free miRNAs released from cancer cells; many studies shown that circulating miRNAs are resistant to 
RNase activity and extreme pH and temperature [63,64]. Although a number of HCC-associated 
miRNAs sets have been identified, only few of them have been validated to assist in diagnosis of HCC. 
Li et al. identified a panel of 13 miRNAs that can serve for HBV-positive HCC diagnosis [65]. 
Moreover, three of these miRNAs (let-7f, miR-375, and miR-25) can discriminate HCC patients from 
healthy subjects. A recent study showed that a seven-miRNAs set (miR-21, miR-26a, miR-27a,  
miR-122, miR-192, miR-223, and miR-801) can differentiate HCC form healthy, chronic hepatitis B 
and cirrhosis groups and it is a promising biomarker for the early HCC diagnosis [66]. Interestingly, 
miRNAs could be powerful markers for classifying HCC subtypes. Based on the expression of AFP 
and EpCAM (epithelial cell adhesion molecule), Yamashita et al. classified HCC cells into EpCAM+ 
AFP+ with metastatic properties and poor prognosis, and EpCAM- AFP- cells with good  
outcome [67,68]. Later, a 20-miRNAs panel has been identified to distinguish HpSC-HCC (hepatic 
stem cell-like hepatocellular carcinoma) from MH-HCC (mature hepatocyte--like hepatocellular 
carcinoma) [69]. These results could significantly predict the two HCC subtypes with an overall 
accuracy of 78% and demonstrated that specific miRNAs are preferentially expressed in HpSC-HCC. 
All of these studies suggest that miRNAs may be useful as novel biomarkers in the early and  
non-invasive detection of HCC. 
5. miRNAs in HCC Prognosis 
Although current markers used for HCC prognosis are still based on clinical parameters, biomarkers 
related to metastasis and disease recurrence might be used as prognostic factors. For example, to 
predict metastatic potential and tumor recurrence Budhu et al. identified a 20-miRNAs signature able 
to classify HCC patients, in every stage [10]. Moreover, it was an indipendent and significant predictor 
of patient prognosis, who would benefit from adjuvant therapy to reduce the chance of metastasis and 
disease recurrence.  
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Wong et al. revealed that miRNAs expression profiles of primary HCC and venous metastasis are 
similar [70]. These data suggest that early miRNAs deregulation prompts later metastatic development 
of primary HCC.  
In a large cohort of patients Ji et al. showed the importance of miR-26 in determining the  
outcome of HCC patients [71]. Especially tumors with reduced miR-26 expression had a distinct  
gene-expression profile, and patients whose tumors had low miR-26 expression, compared with 
patients whose tumors had high miR-26 expression, presented a shorter survival but a better response 
to interferon alfa treatment. 
Recently, Wei et al. identified a novel 20-miRNAs signature that can predict the survival of patients 
with hepatocellular carcinoma [72]. This provides a potentially valuable approach for evaluating the 
prognosis of patients with hepatocellular carcinoma and helping clinicians to design appropriate 
treatment plans. 
6. miRNAs in HCC Treatment 
Recent evidence has suggested the potential application of miRNAs as novel strategy in cancer 
therapy for HCC. In fact, the discovery of miRNAs as an important player in the development and 
progression of HCC has implied that miRNAs can be used as therapeutic agents.  
The complexity of miRNAs biology offers a novel mechanism of action for therapeutic intervention 
but also poses unique challenges for the development of therapeutic modulators as drugs. The 
therapeutic application of miRNAs involves two strategies.  
The first aims to inhibit oncogenic miRNAs by using miRNA antagonists, such as antimiRs, locked 
nucleic acids (LNAs) or antagomiRs [73]. MicroRNA antagonists are single-stranded RNA molecules, 
approximately 21–23 nt long, that act through complementary base-pairing with miRNAs. To achieve 
effective pharmacological inhibition of disease-associated miRNAs, miRNA antagonists contain chemical 
modifications to enhance binding affinity, confer nuclease resistance, and facilitate cellular uptake [73]. 
The second strategy, miRNA replacement, involves the reintroduction of a tumor suppressor 
miRNA mimetic to restore a loss of function [74]. miRNA mimetics represent an additional level of 
complexity compared with antimiRs. This strategy could have the potential to induce unwanted effects 
when novel miRNAs are introduced into a cell, but currently in vivo evidence for toxicity induced by 
miRNA mimetics is still lacking. 
As discussed earlier, because one miRNA can target multiple genes and pathways, artificially 
increasing or decreasing the expression level of a given miRNA could enhance the biological efficacy 
and reduce the risk of resistance to therapy. But, for the same reason, the modulation of miRNAs 
expression could also result in undesiderable off-target effects.  
Another problem of miRNAs-based anticancer therapies is their delivery. One opportunity is 
represented by the adeno-associated viral vectors thanks to the lower risk of vector-related toxicities 
and good gene transfer efficacy. Kota et al. administered systemically mir-26a (its function as tumor 
suppressor by suppressing the G1/S transition and is frequently downregulated in HCC) in a mouse 
model using adeno-associated virus and found that ectopic expression of miR-26a results on inhibiton of 
cancer cell proliferation, induction of tumour-specific apoptosis [75], suggesting the therapeutic 
potential of restoring the expression of a dysregulated miRNAs to treat HCC. Moreover, this work 
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suggests that delivery of miRNAs may provide an important therapeutic strategy. However, its 
significance in patients still need to be confirmed.  
Some works identified a correlation between modulation of cellular miRNAs abundance and the 
sensitivity of HCC cancer cells to chemotherapeutic drugs. Loss of miR-122 facilitates its 
tumourigenic role such as cell migration and survival, while overexpression and restoration of miR-
122 increases the sensitivity of HCC cells to chemotherapeutic agents, such as doxorubicin or 
sorafenib, a multi-kinase inhibitor targeting both Raf and RTKs as well as PDGFR [76–78]. 
From a more clinical point of view, a phase I trial investigating the role of cancer-targeted miRNA 
drug MRX34, a liposome-based miR-34 mimic, is currently undergoing [79]. Further larger trials are 
needed to assess the role of miRNA based drugs in clinical practice [80]. 
7. Conclusions 
miRNAs, small non-coding RNAs that negatively control gene expression, are important players in 
many cellular processes, including carcinogenesis. Aberrantly expressed miRNAs in HCC, associated 
with the identification of miRNA signatures, which are correlated with HCC progression or metastasis, 
make them potential diagnostic and/or prognostic markers and provide novel therapeutic targets for 
HCC treatment. miRNA signatures need to be further validated with high accuracy in future studies 
with larger samples, avoiding variations in the technical procedures, from the method of sampling to 
the method of detection. Furthermore, miRNA-based gene therapy offers a great challenge to improve 
diagnosis and treatment of HCC. 
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